These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37002644)

  • 21. Isatuximab for the treatment of relapsed/refractory multiple myeloma.
    Richardson PG; Beksaç M; Špička I; Mikhael J
    Expert Opin Biol Ther; 2020 Dec; 20(12):1395-1404. PubMed ID: 33111607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.
    Lesokhin A; LeBlanc R; Dimopoulos MA; Capra M; Carlo-Stella C; Karlin L; Castilloux JF; Forsberg P; Parmar G; Tosikyan A; Pour L; Ribrag V; Ribolla R; Abdallah AO; Le Roux N; Dong L; van de Velde H; Mayrargue L; Lépine L; Macé S; Moreau P
    Cancer Med; 2023 May; 12(9):10254-10266. PubMed ID: 36866838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma.
    Reece D; Diels J; Van Sanden S; Pei L; Ammann E; Heuck C; Kane C; Londhe A; Peterson S; Chari A
    Curr Med Res Opin; 2024 Oct; 40(10):1769-1783. PubMed ID: 39226081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
    Martin TG; Shah N; Richter J; Vesole DH; Wong SW; Huang CY; Madduri D; Jagannath S; Siegel DS; Biran N; Wolf JL; Parekh S; Cho HJ; Munster P; Richard S; Ziti-Ljajic S; Chari A
    Cancer; 2021 Jun; 127(11):1816-1826. PubMed ID: 33735504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
    Raab MS; Engelhardt M; Blank A; Goldschmidt H; Agis H; Blau IW; Einsele H; Ferstl B; Schub N; Röllig C; Weisel K; Winderlich M; Griese J; Härtle S; Weirather J; Jarutat T; Peschel C; Chatterjee M
    Lancet Haematol; 2020 May; 7(5):e381-e394. PubMed ID: 32171061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma.
    Suzuki K; Sunami K; Matsumoto M; Maki A; Shimada F; Suzuki K; Shimizu K
    Acta Haematol; 2021; 144(3):264-274. PubMed ID: 33279887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.
    Piggin A; Prince HM
    Expert Rev Hematol; 2021 May; 14(5):419-427. PubMed ID: 33945375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
    Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
    Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
    [No Abstract]   [Full Text] [Related]  

  • 29. Isatuximab: First Approval.
    Dhillon S
    Drugs; 2020 Jun; 80(9):905-912. PubMed ID: 32347476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma.
    Banerjee R; Lo M; Martin TG
    Future Oncol; 2021 Dec; 17(35):4849-4860. PubMed ID: 34553603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Once-weekly (70 mg/m
    Moreau P; Stewart KA; Dimopoulos M; Siegel D; Facon T; Berenson J; Raje N; Berdeja JG; Orlowski RZ; Yang H; Ma H; Klippel Z; Zahlten-Kumeli A; Mezzi K; Iskander K; Mateos MV
    Cancer Med; 2020 May; 9(9):2989-2996. PubMed ID: 32108443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients.
    Fau JB; El-Cheikh R; Brillac C; Koiwai K; Mace N; Campana F; Semiond D; Nguyen L
    CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):649-658. PubMed ID: 33021075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isatuximab: Nursing Considerations for Use in the Treatment of Multiple Myeloma.
    Wilmoth J; Colson K; Dubin F; Kellam C
    Clin J Oncol Nurs; 2021 Dec; 25(6):706-712. PubMed ID: 34800109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study.
    Facon T; Moreau P; Špicka I; Suzuki K; Yong K; Mikhael J; Fukao T; Bisht K; Armstrong NM; Macé S; Risse ML; Martin T
    Hematol Oncol; 2024 Mar; 42(2):e3258. PubMed ID: 38402467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
    Usmani SZ; Karanes C; Bensinger WI; D'Souza A; Raje N; Tuchman SA; Sborov D; Laubach JP; Bianchi G; Kanagavel D; Saleem R; Dubin F; Campana F; Richardson PG
    Leukemia; 2021 Dec; 35(12):3526-3533. PubMed ID: 34050260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma.
    Shah B; Gray J; Abraham I; Chang M
    J Oncol Pharm Pract; 2023 Jan; 29(1):170-182. PubMed ID: 35726199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
    Martin T; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Casca F; Macé S; Risse ML; Moreau P
    Blood Cancer J; 2023 May; 13(1):72. PubMed ID: 37156782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab.
    Shen F; Shen W
    Technol Cancer Res Treat; 2022; 21():15330338221106563. PubMed ID: 35903924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.